Skip to navigation Skip to content

Clinical Trial: Comparing Experimental Fenebrutinib to Ocrevus® in Primary Progressive MS

Share

Details
Type of MS: PPMS
Treatment mode of action: To affect immune function
Number of Subjects: 946
Medication: Fenebrutinib, Ocrevus
Location: Alabama|California|Connecticut|District of Columbia|Florida|Indiana|Kansas|Massachusetts|Minnesota|Missouri|Nevada|New Jersey|New York|North Carolina|Ohio|Tennessee|Texas|Washington|West Virginia|Wisconsin
Institutions: Multiple, worldwide Contact Information
Please see below for contact information.

Funding:

 F. Hoffmann-La Roche

Description

Investigators in the U.S. and abroad are recruiting 946 people with primary progressive MS for a study comparing investigational oral fenebrutinib with Ocrevus® (ocrelizumab - Genentech, a member of the Roche Group). The study – also called FENtrepid – is sponsored by F. Hoffmann-La Roche. Read more

Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please visit the study website at www.fenstudies.com, call 888-662-6728 or email global-roche-genentech-trials@gene.com.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.